疏风解毒胶囊联合炎琥宁注射液治疗小儿上呼吸道感染的临床研究

Clinical study on Shufeng Jiedu Capsules combined with Potassium Sodium Dehydroandrographolide Succinate Injection in treatment of upper respiratory tract infection in children

目的探讨疏风解毒胶囊联合炎琥宁注射液治疗小儿上呼吸道感染的临床效果。方法选取2017年1月—2018年3月青岛市市立医院收治的142例急性上呼吸道感染患儿,随机分为对照组和治疗组,每组各71例。对照组iv炎琥宁注射液,15 mg/kg加入5%葡萄糖液100 m L中均匀混合后给药,1次/d。治疗组在对照组治疗基础上口服疏风解毒胶囊,7≤年龄<10岁,3粒/次;≥10岁,4粒/次,3次/d。两组均连续治疗7 d。观察两组的临床疗效和临床症状消失时间,比较两组治疗前后临床症状积分、血象情况、C反应蛋白(CRP)、肿瘤坏死因子(TNF)-α、白介素(IL)-6、外周血辅助性T细胞(Th)1和Th2亚群比例的变化情况。结果治疗后,对照组和治疗组的总有效率分别为83.1%、94.4%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组发热消失时间、咽红肿消失时间、鼻塞消失时间、流涕消失时间、咳嗽消失时间显著短于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组发热积分、咽红肿积分、鼻塞积分、流涕积分、咳嗽积分、总积分、白细胞总数异常、中性粒细胞数异常、淋巴细胞数异常例数和占比均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组这些症状积分、白细胞总数异常、中性粒细胞数异常、淋巴细胞数异常例数和占比均显著低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清CRP、TNF-α、IL-6、外周血Th1、Th2亚群比例较治疗前均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);治疗后,治疗组CRP、TNF-α、IL-6、外周血Th1、Th2亚群比例显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论疏风解毒胶囊联合炎琥宁注射液治疗小儿上呼吸道感染具有较好的临床疗效,可迅速改善患儿症状和血象,减轻炎性损伤,调节免疫功能,具有一定的临床推广应用价值。

Objective To investigate the clinical effect of Shufeng Jiedu Capsules combined with Potassium Sodium Dehydroandrographolide Succinate Injection in treatment of upper respiratory tract infection in children. Methods Patients（142 cases） with upper respiratory tract infection in Qingdao Municipal Hospital（Group） from January 2017 to December 2018 were randomly divided into control（71 cases） and treatment（71 cases） groups. Patients in the control group were iv administered with Potassium Sodium Dehydroandrographolide Succinate Injection, 15 mg/kg added with 5% glucose solution 100 m L, once daily. Patients in the treatment group were po administered with Shufeng Jiedu Capsules on the basis of the control group, 7≤age〈10, 3 grains/time, age≥10, 4 grains/time, three times daily. Patients in two groups were treated for 7 d. After treatment, the clinical efficacy and clinical symptom disappearance time were evaluated, and the changes of clinical symptom score, blood situation, CRP, TNF-α, IL-6, Th1, and Th2 in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment group were 83.1% and 94.4%, and there were differences between two groups（P 〈 0.05）. After treatment, fever disappeared time, pharyngeal redness disappeared time, nasal congestion disappeared time, runny nose disappeared time, and cough disappeared time in the treatment group were shorter than those in the control group, and there were differences between two groups（P 〈 0.05）. After treatment, fever score, pharyngeal redness score, nasal obstruction score, runny score, cough score, total score, count and proportion of white blood cell abnormal count, neutrophil abnormal count, lymphocyte abnormal were all significantly decreased in two groups, and there were differences in the same group（P 〈 0.05）. After treatment, those symptoms scores, count and proportion of white blood cell abnormal count, neutrophil abnormal count, lymphocyte abnormal in the treatment group were lower than those in the control group, and there were differences between two groups（P 〈 0.05）. After treatment, CRP, TNF-α, IL-6, Th1, and Th2 were all significantly decreased in two groups, and there were differences in the same group（P 〈 0.05）. After treatment, CRP, TNF-α, IL-6, Th1, and Th2 in the treatment group were lower than those in the control group, and there were differences between two groups（P 〈 0.05）. Conclusion Shufeng Jiedu Capsules combined with Potassium Sodium Dehydroandrographolide Succinate Injection has significant clinical effect in treatment of upper respiratory tract infection in children, and can rapidly improve the symptoms and blood situation, also can reduce inflammatory injury, and regulate immune function, which has a certain clinical application value.